Early Cancer Detection: What's Going on and What's Next

Abstract

Late-stage cancer diagnosis and limited treatment options for advanced disease remain major contributors to cancer-related morbidity and mortality. Blood-based multicancer early detection (MCED) assays have consequently gained momentum as a means to shift diagnosis toward earlier, more curable stages. Despite their promise, substantial methodological, clinical, and implementation barriers hinder widespread adoption. Integrative approaches coupling multi-omics profiling with advanced molecular imaging may improve detection accuracy and tumor localization, while risk-adapted MCED paradigms could support more targeted, individualized screening strategies.

This article reviews the current landscape of MCED technologies, with a primary focus on circulating cell-free DNA and circulating tumor DNA–based assays, and critically evaluates their developmental status, strengths, and limitations relative to established single-cancer screening methods. The contribution of artificial intelligence, particularly advanced deep learning, to improving sensitivity, specificity, and predictive performance is discussed. The potential of MCED assays to detect aggressive, currently unscreened malignancies and to address the unique challenges of pediatric cancers is examined. In addition, emerging alternative detection strategies, ongoing clinical validation efforts, regulatory requirements, and implementation considerations are reviewed. Finally, the impact of MCED testing on cancer mortality, quality of life, and healthcare systems is outlined, along with key technological trends shaping future development and clinical translation.

Keywords

artificial intelligence models / circulating cell-free DNA / early cancer diagnosis / liquid biopsy / multicancer early detection tests / tumor-associated biomarkers

References

[1] World Health Organization. “Cancer, Key Facts.” Accessed on January 16, 2025, https://www.who.int/news-room/fact-sheets/detail/cancer.

[2] H. M. Bizuayehu, K. Y. Ahmed, G. D. Kibret, et al., “Global Disparities of Cancer and Its Projected Burden in 2050,” JAMA Network Open 7, no. 11 (2024): e2443198.

[3] N. McGarvey, M. Gitlin, E. Fadli, and K. C. Chung, “Increased Healthcare Costs by Later Stage Cancer Diagnosis,” BMC Health Services Research 22, no. 1 (2022).

[4] American Cancer Society, American Cancer Society Guidelines for the Early Detection of Cancer, January 16, 2026, https://www.cancer.org/cancer/screening/american-cancer-society-guidelines-for-the-early-detection-of-cancer.html.

[5] National Cancer Institute, Surveillance, Epidemiology, and End Results (SEER) Program, January 16, 2026, https://seer.cancer.gov.

[6] C. A. Clarke, E. Hubbell, and J. J. Ofman, “Multi-Cancer Early Detection: A New Paradigm for Reducing Cancer-Specific and All-Cause Mortality,” Cancer Cell 39, no. 4 (2021): 447–448.

[7] J. Vittone, D. Gill, A. Goldsmith, E. A. Klein, and J. J. Karlitz, “A Multi-Cancer Early Detection Blood Test Using Machine Learning Detects Early-Stage Cancers Lacking USPSTF-Recommended Screening,” NPJ Precision Oncology 8, no. 1 (2024).

[8] X. Chen, J. Gole, A. Gore, et al., “Non-Invasive Early Detection of Cancer Four Years Before Conventional Diagnosis Using a Blood Test',” Nature Communications 11, no. 1 (2020).

[9] T. Brito-Rocha, V. Constâncio, R. Henrique, and C. Jerónimo, “Shifting the Cancer Screening Paradigm: The Rising Potential of Blood-Based Multi-Cancer Early Detection Tests,” Cells (Basel, Switzerland) 12, no. 6 (2023): 935.

[10] S. Chakraborty, G. Sharma, S. Karmakar, and S. Banerjee, “Multi-OMICS Approaches in Cancer Biology: New Era in Cancer Therapy,” Biochimica et Biophysica Acta Molecular Basis of Disease 1870, no. 5 (2024): 167120.

[11] T. Wolde, V. Bhardwaj, and V. Pandey, “Current Bioinformatics Tools in Precision Oncology,” MedComm 6, no. 7 (2025).

[12] D. Schrag, T. M. Beer, C. H. McDonnell III, et al., “Blood-Based Tests for Multicancer Early Detection (PATHFINDER): A Prospective Cohort Study,” Lancet 402, no. 10409 (2023): 1251–1260.

[13] C. Swanton, V. Bachtiar, C. Mathews, et al., “NHS-Galleri Trial: Enriched Enrolment Approaches and Sociodemographic Characteristics of Enrolled Participants,” Clinical Trials (London, England) 22, no. 2 (2025): 227–238.

[14] M. Matrana, V. Shukla, D. Kingsbury, et al., “Real-World Data and Clinical Experience From Over 100,000 Multi-Cancer Early Detection Tests,” Nature Communications 16, no. 1 (2025): 9625.

[15] K. C. Gogebakan, J. Lange, L. Owens, et al., “Clinical Significance of a Multicancer Screening Trial With Stage-Based End Points,” JAMA Network Open 8, no. 10 (2025): e2536247.

[16] R. Gupta, T. Othman, C. Chen, J. Sandhu, C. Ouyang, and M. Fakih, “Guardant360 Circulating Tumor DNA Assay Is Concordant With FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naive Metastatic Colorectal Cancer,” Oncologist 25, no. 3 (2020): 235–243.

[17] J. M. Bauml, B. T. Li, V. Velcheti, et al., “Clinical Validation of Guardant360 CDx as a Blood-Based Companion Diagnostic for Sotorasib,” Lung Cancer (Amsterdam, Netherlands) 166 (2022): 270–278.

[18] H. Q. Abbasi, M. Adeena, A. M. Khan, S. Shahnoor, M. O. Oduoye, and W. P. Nafula, “Advancing Precision Oncology in Breast Cancer: The FDA Approval of Elacestrant and Guardant 360CDx: A Correspondence,” , Publish Ahead of Print (2023), https://doi.org/10.1097/js9.0000000000000334.

[19] A. Campos-Carrillo, J. N. Weitzel, and P. Sahoo, “Circulating Tumor DNA as an Early Cancer Detection Tool,” Pharmacology & Therapeutics 207, no. 107458 (2020): 107458.

[20] C. Fiala, V. Kulasingam, and E. P. Diamandis, “Circulating Tumor DNA for Early Cancer Detection,” Journal of Applied Laboratory Medicine 3, no. 2 (2018): 300–313.

[21] D. C. Chung, M. Darrell, I. I. Gray, et al., “A Cell-Free DNA Blood-Based Test for Colorectal Cancer Screening,” New England Journal of Medicine 390, no. 11 (2024): 973–983.

[22] J. T. Topham, C. J. O'Callaghan, H. Feilotter, et al., “Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer,” Journal of Clinical Oncology 41, no. 3 (2023): 485–496.

[23] A. M. Aravanis, M. Lee, and R. D. Klausner, “Next-Generation Sequencing of Circulating Tumor DNA for Early Cancer Detection,” Cell 168, no. 4 (2017): 571–574.

[24] E.-A. Raiber-Moreau, G. Portella, M. G. Butler, O. Clement, Y. Konigshofer, and J. Hadfield, “Development and Validation of Blood Tumor Mutational Burden Reference Standards,” Genes, Chromosomes & Cancer 62, no. 3 (2023): 121–130.

[25] C. Chen, Z. Wang, Y. Ding, et al., “DNA Methylation: From Cancer Biology to Clinical Perspectives,” Frontiers in Bioscience-Landmark 27, no. 12 (2022).

[26] E. LeeVan and P. Pinsky, “Predictive Performance of Cell-Free Nucleic Acid-Based Multi-Cancer Early Detection Tests: A Systematic Review,” Clinical Chemistry 70 (2024): 90–101.

[27] N. C. V. Van Thien, T. H. Hanh Nguyen, D. H. Vo, et al., “Evaluation of a Multimodal ctDNA-Based Assay for Detection of Aggressive Cancers Lacking Standard Screening Tests,” Future Oncology (London, England) 21, no. 1 (2025): 105–115.

[28] R. D. Neal, P. Johnson, C. A. Clarke, et al., “Cell-Free DNA–Based Multi-Cancer Early Detection Test in an Asymptomatic Screening Population (NHS-Galleri): Design of a Pragmatic, Prospective Randomised Controlled Trial',” Cancers 14, no. 19 (2022): 4818.

[29] B. D. Nicholson, J. Oke, P. S. Virdee, et al., “Multi-Cancer Early Detection Test in Symptomatic Patients Referred for Cancer Investigation in England and Wales (SYMPLIFY): A Large-Scale, Observational Cohort Study,” The Lancet Oncology 24, no. 7 (2023): 733–743.

[30] J. B. Kisiel, J. O. Ebbert, W. R. Taylor, et al., “Shifting the Cancer Screening Paradigm: Developing a Multi-Biomarker Class Approach to Multi-Cancer Early Detection Testing,” Life (Basel, Switzerland) 14, no. 8 (2024): 925.

[31] M. S. Hussain, M. Rejili, A. Khan, et al., “AI-Powered Liquid Biopsy for Early Detection of Gastrointestinal Cancers',” Clinica Chimica Acta; International Journal of Clinical Chemistry 577, no. 120484 (2025): 120484.

[32] H.-Y. Wang, W.-Y. Lin, C. Zhou, Z.-A. Yang, S. Kalpana, and M. S. Lebowitz, “Integrating Artificial Intelligence for Advancing Multiple-Cancer Early Detection via Serum Biomarkers: A Narrative Review,” Cancers 16, no. 5 (2024): 862.

[33] M. Dong, L. Wang, N. Hu, Y. Rao, Z. Wang, and Y. Zhang, “Integration of Multi-Omics Approaches in Exploring Intra-Tumoral Heterogeneity,” Cancer Cell International 25, no. 1 (2025).

[34] W. H. A. Tsui, S. C. Ding, P. Jiang, and Y. M. Dennis Lo, “Artificial Intelligence and Machine Learning in Cell-Free-DNA-Based Diagnostics,” Genome Research 35, no. 1 (2025): 1–19.

[35] T.-G. Chang, S. Park, A. A. Schäffer, P. Jiang, and E. Ruppin, “Hallmarks of Artificial Intelligence Contributions to Precision Oncology,” Nature Cancer 6, no. 3 (2025): 417–431.

[36] L. Breiman, “Random Forests,” Machine learning 45, no. 1 (2001): 5–32.

[37] I. Ahmad and F. Alqurashi, “Early Cancer Detection Using Deep Learning and Medical Imaging: A Survey,” Critical Reviews in Oncology/Hematology 204, no. 104528 (2024): 104528.

[38] Y. Hussain Ali, V. S. Chooralil, K. Balasubramanian, et al., “Optimization System Based on Convolutional Neural Network and Internet of Medical Things for Early Diagnosis of Lung Cancer,” Bioengineering (Basel, Switzerland) 10, no. 3 (2023): 320.

[39] Y. Xu, S. Zhu, C. Xia, et al., “Liquid Biopsy-Based Multi-Cancer Early Detection: An Exploration Road From Evidence to Implementation,” Science Bulletin 17 (2025): 2852–2867.

[40] J. Wang, W. Zhang, H. Li, Y. Wang, J. Qi, and J. Nie, “Cell-Free DNA Methylation and Fragmentomics-Based Liquid Biopsy for Accurate Esophageal Cancer Detection,” BMC Cancer 25, no. 1 (2025).

[41] W. H. A. Tsui, P. Jiang, and Y. M. Dennis Lo, “Cell-Free DNA Fragmentomics in Cancer,” Cancer Cell 43, no. 10 (2025): 1792–1814.

[42] L. Lu, Y. Wang, and X. Zhou, “Early Cancer Detection via Multi-Omics cfDNA Fragmentation Using Early-Late Fusion Neural Network With Sample-Modality Evaluation,” Briefings in Bioinformatics 26, no. 6 (2025).

[43] A. Zviran, R. C. Schulman, M. Shah, et al., “Genome-Wide Cell-Free DNA Mutational Integration Enables Ultra-Sensitive Cancer Monitoring,” Nature Medicine 26, no. 7 (2020): 1114–1124.

[44] F. Alharbi and A. Vakanski, “Machine Learning Methods for Cancer Classification Using Gene Expression Data: A Review,” Bioengineering (Basel, Switzerland) 10, no. 2 (2023): 173.

[45] Y. Pomyen, K. Wanichthanarak, P. Poungsombat, J. Fahrmann, D. Grapov, and S. Khoomrung, “Deep Metabolome: Applications of Deep Learning in Metabolomics,” Computational and Structural Biotechnology Journal 18 (2020): 2818–2825.

[46] X. Jia and C. Papadimitriou, “Hierarchical Bayesian Learning Framework for Multi-Level Modeling Using Multi-Level Data,” Mechanical Systems and Signal Processing 179, no. 109179 (2022): 109179.

[47] N. Kryuchkova-Mostacci and M. Robinson-Rechavi, “A Benchmark of Gene Expression Tissue-Specificity Metrics,” Briefings in Bioinformatics (2016): bbw008.

[48] S. S. Qian, S. Jaffe, E. Gionfriddo, H. Wang, C. J. Richardson, and N. H. Godage, “Rethinking Calibration as a Statistical Estimation Problem to Improve Measurement Accuracy',” Analytica Chimica Acta 1372, no. 344395 (2025): 34439.

[49] M. C. Liu, G. R. Oxnard, E. A. Klein, C. Swanton, M. V. Seiden, and C. Consortium, “Sensitive and Specific Multi-Cancer Detection and Localization Using Methylation Signatures in Cell-Free DNA,” Annals of Oncology 31, no. 6 (2020): 745–759.

[50] K. Fernald and M. Kurokawa, “Evading Apoptosis in Cancer,” Trends in Cell Biology 12 (2013): 620–633.

[51] D. Hanahan, “Hallmarks of Cancer: New Dimensions,” Cancer Discovery 1 (2022): 31–46.

[52] L. E. L. Hendriks, J. Remon, C. Faivre-Finn, et al., “Non-Small-Cell Lung Cancer,” Nature Reviews Disease Primers 10, no. 1 (2024).

[53] D. Bugazia, E. Al-Najjar, A. Esmail, et al., “Pancreatic Ductal Adenocarcinoma: The Latest on Diagnosis, Molecular Profiling, and Systemic Treatments,” Frontiers in Oncology 14, no. 1386699 (2024).

[54] N. Xiong, H. Wu, and Z. Yu, “Advancements and Challenges in Triple-Negative Breast Cancer: A Comprehensive Review of Therapeutic and Diagnostic Strategies,” Frontiers in Oncology 14, no. 1405491 (2024).

[55] G. V. Long, S. M. Swetter, A. M. Menzies, J. E. Gershenwald, and R. A. Scolyer, “Cutaneous Melanoma',” Lancet 402, no. 10400 (2023): 485–502.

[56] M. Roerden and S. Spranger, “Cancer Immune Evasion, Immunoediting and Intratumour Heterogeneity',” Nature Reviews Immunology 25, no. 5 (2025): 353–369.

[57] A. C. Swain, J. A. M. Borghans, and R. J. Boer, “How Are Estimated Cellular Turnover Rates Influenced by the Dynamics of a Source Population?,” PLoS Computational Biology 21, no. 5 (2025): e1013052.

[58] Z. Hu, H. Chen, Y. Long, P. Li, and Y. Gu, “The Main Sources of Circulating Cell-Free DNA: Apoptosis, Necrosis and Active Secretion,” Critical Reviews in Oncology/Hematology 157, no. 103166 (2021): 103166.

[59] S. Avanzini, D. M. Kurtz, J. J. Chabon, et al., “A Mathematical Model of ctDNA Shedding Predicts Tumor Detection Size,” Science Advances 6, no. 50 (2020).

[60] A. L. Harris, D. J. Kerr, F. Pezzella, and D. Ribatti, “Accessing the Vasculature in Cancer: Revising an Old Hallmark',” Trends in Cancer 10, no. 11 (2024): 1038–1051.

[61] P. Shrestha, Z. S. Ghoreyshi, and J. T. George, “How Modulation of the Tumor Microenvironment Drives Cancer Immune Escape Dynamics,” Scientific Reports 15, no. 1 (2025): 7308.

[62] S. Valpione, G. Gremel, P. Mundra, et al., “Plasma Total Cell-Free DNA (cfDNA) Is a Surrogate Biomarker for Tumour Burden and a Prognostic Biomarker for Survival in Metastatic Melanoma Patients,” European Journal of Cancer (Oxford, England: 1990) 88 (2018): 1–9.

[63] A. Rostami, M. Lambie, C. W. Yu, V. Stambolic, J. N. Waldron, and S. V. Bratman, “Senescence, Necrosis, and Apoptosis Govern Circulating Cell-Free DNA Release Kinetics,” Cell Reports 13 (2020): 107830.

[64] H. Chen, J. Carrot-Zhang, Y. Zhao, et al., “Genomic and Immune Profiling of Pre-Invasive Lung Adenocarcinoma,” Nature Communications 10, no. 1 (2019).

[65] J. Wang, B. Li, M. Luo, et al., “Progression From Ductal Carcinoma in Situ to Invasive Breast Cancer: Molecular Features and Clinical Significance,” Signal Transduction and Targeted Therapy 9, no. 1 (2024).

[66] J. D. Subiela, O. R. Faba, F. G. Ramos, et al., “Carcinoma in Situ of the Urinary Bladder: A Systematic Review of Current Knowledge Regarding Detection, Treatment, and Outcomes,” European Urology Focus 6, no. 4 (2020): 674–682.

[67] S.-H. Lin, G. S. Raju, C. Huff, et al., “The Somatic Mutation Landscape of Premalignant Colorectal Adenoma,” Gut 67, no. 7 (2018): 1299–1305.

[68] L. Giannella, G. Delli Carpini, J. Di Giuseppe, et al., “Situ/Microinvasive Adenocarcinoma of the Uterine Cervix and HPV-Type Impact: Pathologic Features, Treatment Options, and Follow-up Outcomes—Cervical Adenocarcinoma Study Group (CAS-Group),” Cancers 15, no. 11 (2023): 2876.

[69] D. Teoh, F. Musa, R. Salani, W. Huh, and E. Jimenez, “Diagnosis and Management of Adenocarcinoma in Situ,” Obstetrics and Gynecology 135, no. 4 (2020): 869–878.

[70] M. B. Daly, T. Pal, K. N. Maxwell, et al., “NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024,” Journal of the National Comprehensive Cancer Network 21, no. 10 (2023): 1000–1010.

[71] C. Thakur, U. Saran, and F. Chen, “Editorial: The Impact of Specific Environmental Exposures on Breast, Lung, and Colon Cancer: Advancing Public Health Strategies for Enhanced Outcomes,” Frontiers in Public Health 13 (2025): 1483915.

[72] I. Z. Sadiq, “Environmental Carcinogens and Cancer Risk: Sustainable Strategies for Public Health Protection',” Chemosphere 385, no. 144580 (2025): 144580.

[73] C. Hu, S. N. Hart, E. C. Polley, et al., “Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer,” The Journal of the American Medical Association 319, no. 23 (2018): 2401.

[74] K. Abe, M. Kitago, Y. Kitagawa, and A. Hirasawa, “Hereditary Pancreatic Cancer,” International Journal of Clinical Oncology 10 (2021): 1784–1792.

[75] F. Fostira, M. Papadimitriou, and C. Papadimitriou, “Current Practices on Genetic Testing in Ovarian Cancer,” Annals of Translational Medicine 8, no. 24 (2020): 1703, https://doi.org/10.21037/atm-20-1422.

[76] J. Ngeow, J. Chiang, E. Astiazaran-Symonds, et al., “Management of Individuals With Heterozygous Germline Pathogenic Variants in RAD51C, RAD51D, and BRIP1: A Clinical Practice Resource of the American College of Medical Genetics and Genomics (ACMG)',” Genetics in Medicine: Official Journal of the American College of Medical Genetics 27, no. 11 (2025): 101557.

[77] R. S. V. D. Post, I. P. Vogelaar, F. Carneiro, et al., “Hereditary Diffuse Gastric Cancer: Updated Clinical Guidelines With an Emphasis on Germline CDH1 Mutation Carriers,” Journal of Medical Genetics 52, no. 6 (2015): 361–374.

[78] M. D. Stachler, N. D. Camarda, C. Deitrick, et al., “Detection of Mutations in Barrett's Esophagus Before Progression to High-Grade Dysplasia or Adenocarcinoma,” Gastroenterology 155, no. 1 (2018): 156–167.

[79] European Association for the Study of the Liver. “EASL Clinical Practice Guidelines on Haemochromatosis”. Journal of Hepatology 77, no. 2 (2022): 479–502.

[80] C. V. Schneider, M. Decraecker, A. Beaufrère, et al., “Alpha-1 Antitrypsin Deficiency and Primary Liver Cancers,” Biochimica et Biophysica Acta Reviews on Cancer 1880, no. 2 (2025): 189290.

[81] H. Maynard, Z. K. Stadler, M. F. Berger, et al., “Germline Alterations in Patients With Biliary Tract Cancers: A Spectrum of Significant and Previously Underappreciated Findings,” Cancer 126, no. 9 (2020): 1995–2002.

[82] J. Choi and M. Jung, “Head and Neck Cancer in Fanconi Anemia: Clinical Challenges and Molecular Insights Into a DNA Repair Disorder,” Cancers 17, no. 18 (2025): 3046.

[83] H. Liu, G. Li, E. M. Sturgis, et al., “Genetic Variants in CYP2B6 and HSD17B12 Associated With Risk of Squamous Cell Carcinoma of the Head and Neck,” International Journal of Cancer Journal International Du Cancer 151, no. 4 (2022): 553–564.

[84] E. Ebrahimi, A. Sangphukieo, H. A. Park, et al., “Cross-Ancestral GWAS Identifies 29 Variants Across Head and Neck Cancer Subsites,” Nature Communications 16, no. 1 (2025): 8787.

[85] S. Y. Kim, S. Jeong, W. Lee, et al., “Cancer Signature Ensemble Integrating cfDNA Methylation, Copy Number, and Fragmentation Facilitates Multi-Cancer Early Detection,” Experimental & Molecular Medicine 55, no. 11 (2023): 2445–2460.

[86] V. T. C. Nguyen, T. H. Nguyen, N. N. T. Doan, et al., “Multimodal Analysis of Methylomics and Fragmentomics in Plasma Cell-Free DNA for Multi-Cancer Early Detection and Localization,” Elife 12, no. RP89083 (2023), https://doi.org/10.7554/eLife.89083.

[87] R. Silva, B. Moran, A.-M. Baird, et al., “Longitudinal Analysis of Individual cfDNA Methylome Patterns in Metastatic Prostate Cancer,” Clinical Epigenetics 13, no. 1 (2021): 168.

[88] M. A. Gouda, H. J. Huang, S. A. Piha-Paul, et al., “Longitudinal Monitoring of Circulating Tumor DNA to Predict Treatment Outcomes in Advanced Cancers,” JCO Precision Oncology 6, no. 6 (2022): e2100512.

[89] A. Frydendahl, M. Heilskov Rasmussen, S. Ø. S. Jensen, et al., “Error-Corrected Deep Targeted Sequencing of Circulating Cell-Free DNA From Colorectal Cancer Patients for Sensitive Detection of Circulating Tumor DNA,” International Journal of Molecular Sciences 25, no. 8 (2024): 4252.

[90] S. Shin, S. Han, J. Kim, Y. Shin, J. I.-J. Song, and S. Hohng, “Fast, Sensitive, and Specific Multiplexed Single-Molecule Detection of Circulating Tumor DNA,” Biosensors & Bioelectronics 242, no. 115694 (2023): 115694.

[91] S. Shin, J. Kim, E. Song, S. Han, and S. Hohng, “Analytical Techniques for Nucleic Acid and Protein Detection With Single-Molecule Sensitivity,” Experimental & Molecular Medicine 57, no. 5 (2025): 938–949.

[92] Q. Wang, L. Wu, J. Yu, et al., “Comparison of Tumor and Two Types of Paratumoral Tissues Highlighted Epigenetic Regulation of Transcription During Field Cancerization in Non-Small Cell Lung Cancer,” BMC Medical Genomics 15, no. 1 (2022): 66.

[93] J. Yates, H. Schaufelberger, R. Steinacher, P. Schär, K. Truninger, and V. Boeva, “DNA-Methylation Variability in Normal Mucosa: A Field Cancerization Marker in Patients With Adenomatous Polyps,” Journal of the National Cancer Institute 116, no. 6 (2024): 974–982.

[94] L. Yunduo, S.-Y. Shin, and N. Lan K, “From Shallow to Deep: The Evolution of Machine Learning and Mechanistic Model Integration in Cancer Research,” Current Opinion in Systems Biology 40 no. 100541 (2025): 100541, https://doi.org/10.1016/j.coisb.2025.100541.

[95] P. Mascheroni, S. Savvopoulos, J. C. L. Alfonso, M. Meyer-Hermann, and H. Hatzikirou, “Improving Personalized Tumor Growth Predictions Using a Bayesian Combination of Mechanistic Modeling and Machine Learning,” Communications Medicine 1, no. 1 (2021): 19.

[96] E. A. Klein, D. Richards, A. Cohn, et al., “Clinical Validation of a Targeted Methylation-Based Multi-Cancer Early Detection Test Using an Independent Validation Set,” Annals of Oncology 32, no. 9 (2021): 1167–1177.

[97] J. B. Kisiel, N. Papadopoulos, M. C. Liu, D. Crosby, S. Srivastava, and E. T. Hawk, “Multicancer Early Detection Test: Preclinical, Translational, and Clinical Evidence–Generation Plan and Provocative Questions,” Cancer 128, no. S4 ( 2022): 861–874.

[98] I. Lowenhoff, S. Dolly, R. D. Smith, et al., “Clinical Referral to the NHS Following Multi-Cancer Early Detection Test Results From the NHS-Galleri Trial,” Frontiers in Oncology 15, no. 1511816 (2025), https://doi.org/10.3389/fonc.2025.1511816.

[99] E. LeeVan, A. L. Skarlupka, C. Patriotis, et al., “Framework to Select Multi-Cancer Detection Assays in the National Cancer Institute's Vanguard Study,” Cancer Epidemiology, Biomarkers & Prevention 10 (2025): 1787–1793.

[100] M. McCartney and D. Cohen, “Galleri Promises to Detect Multiple Cancers—but New Evidence Casts Doubt on this Much Hyped Blood Test: Video 1,” BMJ (Clinical Research Ed) (2024): q1706, https://doi.org/10.1136/bmj.q1706.

[101] Y. Cao, N. Wang, X. Wu, et al., “Multidimensional Fragmentomics Enables Early and Accurate Detection of Colorectal Cancer,” Cancer Research 84, no. 19 (2024): 3286–3295.

[102] S. Wang, F. Meng, M. Li, et al., “Multidimensional Cell-Free DNA Fragmentomic Assay for Detection of Early-Stage Lung Cancer,” American Journal of Respiratory and Critical Care Medicine 207, no. 9 (2023): 1203–1213.

[103] Accessed on January 16, 2026, https://precisionepigenomics.com/tests.

[104] Accessed on January 16, 2026, https://www.exactsciences.com.

[105] Accessed on January 16, 2026, https://harbinger-health.com.

[106] Accessed on January 16, 2026, https://www.documo.guardanthealth.com.

[107] Accessed on January 16, 2026, https://www.seekincancer.com.

[108] S. Geng, S. Li, W. Wu, Y. Chang, and M. Mao, “A Cost-Effective Two-Step Approach for Multi-Cancer Early Detection in High-Risk Populations,” Cancer Research Communications 5, no. 1 (2025): 150–156.

[109] W. Wang, Z. Rong, G. Wang, Y. Hou, F. Yang, and M. Qiu, “Cancer Metabolites: Promising Biomarkers for Cancer Liquid Biopsy,” Biomarker Research 11, no. 1 (2023), https://doi.org/10.1186/s40364-023-00507-3.

[110] M. Bhardwaj, A. Gies, S. Werner, P. Schrotz-King, and H. Brenner, “Blood-Based Protein Signatures for Early Detection of Colorectal Cancer: A Systematic Review,” Clinical and Translational Gastroenterology 8, no. 11 (2017): e128.

[111] P. Karihtala, S.-K. Leivonen, U. Puistola, et al., “Serum Protein Profiling Reveals an Inflammation Signature as a Predictor of Early Breast Cancer Survival,” Breast Cancer Research 26, no. 1 (2024), https://doi.org/10.1186/s13058-024-01812-x.

[112] U. Landegren and M. Hammond, “Cancer Diagnostics Based on Plasma Protein Biomarkers: Hard Times but Great Expectations,” Molecular Oncology 15, no. 6 (2021): 1715–1726.

[113] J. L. Montoya Mira, A. Quentel, R. K. Patel, et al., “Early Detection of Pancreatic Cancer by a High-Throughput Protease-Activated Nanosensor Assay,” Science Translational Medicine 17, no. 785 (2025), https://doi.org/10.1126/scitranslmed.adq3110.

[114] D. S. Dkhar, S. Mahapatra, and P. Chandra, “An Electrochemically Charged Nanoengineered Bioelectronic Immunosensing Device for Osteopontin Detection in Serum Samples,” Nanoscale 17, no. 22 (2025): 13668–13684.

[115] M. Imai, Y. Nakamura, and T. Yoshino, “Transforming Cancer Screening: The Potential of Multi-Cancer Early Detection (MCED) Technologies',” International Journal of Clinical Oncology 30, no. 2 (2025): 180–193.

[116] J. O. Ebbert, E. T. Hawk, C. V. Chambers, et al., “Multi-Cancer Early Detection Tests: Attributes for Clinical Implementation,” Cancer Biomarkers: Section A of Disease Markers 42, no. 2 (2025), https://doi.org/10.1177/18758592241297849.

[117] S. K. Kang, R. Gulati, N. Moise, C. Hur, and E. B. Elkin, “Multi-Cancer Early Detection Tests: State of the Art and Implications for Radiologists,” Radiology 314, no. 1 (2025), https://doi.org/10.1148/radiol.233448.

[118] C. E. Guerra, P. V. Sharma, and B. S. Castillo, “Multi-Cancer Early Detection: The New Frontier in Cancer Early Detection,” Annual Review of Medicine 75, no. 1 (2024): 67–81.

[119] C. Carbonell, J. M. Hutchinson, R. J. Hilsden, H. Yang, and D. R. Brenner, “Blood-Based Multi-Cancer Early Detection Tests (MCEDs) as a Potential Approach to Address Current Gaps in Cancer Screening,” Cancer Control: Journal of the Moffitt Cancer Center 31, no. 10732748241307360 (2024), https://doi.org/10.1177/10732748241307360.

[120] L. Kessler, M. M. L. Beau, R. A. Smith, F. M. Walter, and R. Wender, “The Modeling of Multicancer Early Detection (MCED) Tests' Residual Risk and the Challenges of MCED Evaluation and Implementation,” Cancer 129, no. 13 (2023): 1966–1968.

[121] W. S. Rubinstein, C. Patriotis, A. Dickherber, et al., “Cancer Screening With Multicancer Detection Tests: A Translational Science Review,” CA: A Cancer Journal for Clinicians 74, no. 4 (2024): 368–382.

[122] N. Liang, B. Li, Z. Jia, et al., “Author Correction: Ultrasensitive Detection of Circulating Tumour DNA via Deep Methylation Sequencing Aided by Machine Learning,” Nature Biomedical Engineering 5, no. 11 (2021): 1402–1402.

[123] D. A. Milner and J. K. Lennerz, “Technology and Future of Multi-Cancer Early Detection,” Life (Basel, Switzerland) 14, no. 7 (2024): 833.

[124] S. B. Baylin and P. A. Jones, “A Decade of Exploring the Cancer Epigenome — Biological and Translational Implications,” Nature Reviews Cancer 11, no. 10 (2011): 726–734.

[125] J. M. Cameron, A. Sala, G. Antoniou, et al., “A Spectroscopic Liquid Biopsy for the Earlier Detection of Multiple Cancer Types,” British Journal of Cancer 129, no. 10 (2023): 1658–1666.

[126] W. T. Johnston, F. Erdmann, R. Newton, E. Steliarova-Foucher, J. Schüz, and E. Roman, “Childhood Cancer: Estimating Regional and Global Incidence,” Cancer Epidemiology 71, no. 101662 (2021): 101662.

[127] S. N. Gröbner, B. C. Worst, J. Weischenfeldt, et al., “The Landscape of Genomic Alterations Across Childhood Cancers,” Nature 555, no. 7696 (2018): 321–327.

[128] L. S. Manuel, D. Andersson, T. Z. Parris, K. Helou, T. Österlund, and A. Ståhlberg, “Digital RNA Sequencing Using Unique Molecular Identifiers Enables Ultrasensitive RNA Mutation Analysis,” Communications Biology 7, no. 1 (2024), https://doi.org/10.1038/s42003-024-05955-7.

[129] C. H. Li, S. Haider, and P. C. Boutros, “Age Influences on the Molecular Presentation of Tumours',” Nature Communications 13, no. 1 (2022), https://doi.org/10.1038/s41467-021-27889-y.

[130] M. C. Hiemenz, D. G. Ostrow, T. M. Busse, et al., “OncoKids,” The Journal of Molecular Diagnostics 20, no. 6 (2018): 765–776.

[131] M. Picard, M.-P. Scott-Boyer, A. Bodein, O. Périn, and A. Droit, “Integration Strategies of Multi-Omics Data for Machine Learning Analysis,” Computational and Structural Biotechnology Journal 19 (2021): 3735–3746.

[132] G. Olatunji, E. Kokori, N. Aderinto, et al., “Challenges and Strategies in Pediatric Critical Care: Insights From Low-Resource Settings,” Global Pediatric Health 11, no. 2333794×241285964 (2024), https://doi.org/10.1177/2333794×241285964.

[133] Y. J. Heo, C. Hwa, G.-H. Lee, J.-M. Park, and J.-Y. An, “Integrative Multi-Omics Approaches in Cancer Research: From Biological Networks to Clinical Subtypes,” Molecules and Cells 44, no. 7 (2021): 433–443.

[134] A. Villani, A. Shore, J. D. Wasserman, et al., “Biochemical and Imaging Surveillance in Germline TP53 Mutation Carriers With Li-Fraumeni Syndrome: 11 Year Follow-up of a Prospective Observational Study,” The Lancet Oncology 17, no. 9 (2016): 1295–1305.

[135] I. Evans, H. Thornton, I. Chalmers, and P. Glasziou, Testing Treatments: Better Research for Better Healthcare, 2nd ed., (Pinter & Martin, 2011).

[136] B. M. Knoppers, M. H. Zawati, and E. S. Kirby, “Sampling Populations of Humans Across the World: ELSI Issues,” Annual Review of Genomics and Human Genetics 13, no. 1 (2012): 395–413.

[137] K. E. Ormond, A. Blasimme, and E. Vayena, “Ethical Aspects of Pediatric Genetic Care,” Pediatric Clinics of North America 70, no. 5 (2023): 1029–1046.

[138] M. Cho, Z. Qiu, J. Ye, H. Quan, and P.-L. Zhao, “Considerations for Pediatric Trial Designs and Analyses,” Journal of Biopharmaceutical Statistics 28, no. 3 (2018): 413–436.

[139] N. Iragorri and E. Spackman, “Assessing the Value of Screening Tools: Reviewing the Challenges and Opportunities of Cost-Effectiveness Analysis,” Public Health Reviews 39, no. 1 (2018), https://doi.org/10.1186/s40985-018-0093-8.

[140] Z. Obermeyer, B. Powers, C. Vogeli, and S. Mullainathan, “Dissecting Racial Bias in an Algorithm Used to Manage the Health of Populations,” Science (New York, NY) 366, no. 6464 (2019): 447–453.

[141] C. Urla, M. J. Stagno, A. Schmidt, et al., “Epitope Detection in Monocytes (EDIM) as a New Method of Liquid Biopsy in Pediatric Rhabdomyosarcoma,” Biomedicines 10, no. 8 (2022): 1812.

[142] M. J. Stagno, A. Schmidt, J. Bochem, et al., “Epitope Detection in Monocytes (EDIM) for Liquid Biopsy Including Identification of GD2 in Childhood Neuroblastoma—a Pilot Study,” British Journal of Cancer 127, no. 7 (2022): 1324–1331.

[143] F. W. Janssen, N. S. M. Lak, C. Y. Janda, et al., “A Comprehensive Overview of Liquid Biopsy Applications in Pediatric Solid Tumors,” NPJ Precision Oncology 8, no. 1 (2024), https://doi.org/10.1038/s41698-024-00657-z.

[144] J. Coy, “EDIM-TKTL1/Apo10 Blood Test: An Innate Immune System Based Liquid Biopsy for the Early Detection, Characterization and Targeted Treatment of Cancer,” International Journal of Molecular Sciences 18, no. 4 (2017): 878.

[145] E. Furuta, H. Okuda, A. Kobayashi, and K. Watabe, “Metabolic Genes in Cancer: Their Roles in Tumor Progression and Clinical Implications,” Biochimica et Biophysica Acta Reviews on Cancer 1805, no. 2 (2010): 141–152.

[146] X. Xu, A. zur Hausen, J. F. Coy, and M. Löchelt, “Transketolase-Like Protein 1 (TKTL1) Is Required for Rapid Cell Growth and Full Viability of Human Tumor Cells,” International Journal of Cancer Journal International Du Cancer 124, no. 6 (2009): 1330–1337.

[147] A. Jayachandran, P.-H. Lo, A. C. Chueh, et al., “Transketolase-Like 1 Ectopic Expression Is Associated With DNA Hypomethylation and Induces the Warburg Effect in Melanoma Cells,” BMC Cancer 16, no. 1 (2016), https://doi.org/10.1186/s12885-016-2185-5.

[148] S. Hao, Q. Meng, H. Sun, et al., “The Role of Transketolase in Human Cancer Progression and Therapy,” Biomedecine & Pharmacotherapie [Biomedicine & Pharmacotherapy] 154, no. 113607 (2022): 113607.

[149] M. Los, D. Neubüser, J. F. Coy, M. Mozoluk, A. Poustka, and K. Schulze-Osthoff, “Functional Characterization of DNase X, a Novel Endonuclease Expressed in Muscle Cells,” Biochemistry 39, no. 25 (2000): 7365–7373.

[150] M. Grimm, S. Schmitt, P. Teriete, et al., “A Biomarker Based Detection and Characterization of Carcinomas Exploiting Two Fundamental Biophysical Mechanisms in Mammalian Cells,” BMC Cancer 13, no. 1 (2013), https://doi.org/10.1186/1471-2407-13-569.

[151] P. Machy, E. Mortier, and S. Birklé, “Biology of GD2 Ganglioside: Implications for Cancer Immunotherapy,” Frontiers in Pharmacology 14, no. 1249929 (2023), https://doi.org/10.3389/fphar.2023.1249929.

[152] A. C. Fernández-Rilo, E. D. Billy, G. D. Baldo, et al., “'GD2: Hopes and Challenges for the Treatment of Pediatric Patients With Tumors of the Central Nervous System,” Npj Precision Oncology 9, no. 1 (2025), https://doi.org/10.1038/s41698-025-01079-1.

[153] P. Jin and X. Bai, “Exploring the Roles and Clinical Potential of Exosome-Derived Non-Coding RNAs in Glioma,” IBRO Neuroscience Reports 18 (2025): 323–337.

[154] R. Marima, A. Basera, T. Miya, et al., “Exosomal Long Non-Coding RNAs in Cancer: Interplay, Modulation, and Therapeutic Avenues,” Non-Coding RNA Research 9, no. 3 (2024): 887–900.

[155] N. Saffari, S. Rahgozar, E. Faraji, and F. Sahin, “Plasma-Derived Exosomal miR-326, a Prognostic Biomarker and Novel Candidate for Treatment of Drug Resistant Pediatric Acute Lymphoblastic Leukemia,” Scientific Reports 14, no. 1 (2024), https://doi.org/10.1038/s41598-023-50628-w.

[156] Á. G. Tűzesi, T. Kling, A. Wenger, et al., “Pediatric Brain Tumor Cells Release Exosomes With a miRNA Repertoire That Differs From Exosomes Secreted by Normal Cells,” Oncotarget 8, no. 52 (2017): 90164–90175.

[157] G. Kim, H.-J. An, M.-J. Lee, et al., “Hsa-miR-1246 and Hsa-miR-1290 Are Associated With Stemness and Invasiveness of Non-Small Cell Lung Cancer,” Lung Cancer (Amsterdam, Netherlands) 91 (2016): 15–22.

[158] P. Zhang, G. Samuel, J. Crow, A. K. Godwin, and Y. Zeng, “Molecular Assessment of Circulating Exosomes Toward Liquid Biopsy Diagnosis of Ewing Sarcoma Family of Tumors,” Translational Research 201 (2018): 136–153.

[159] S. Hussain, M. G. Gupta, N. Ghaboura, et al., “Exosomal ncRNAs in Liquid Biopsies for Lung Cancer,” Clinica Chimica Acta; International Journal of Clinical Chemistry 565, no. 119983 (2025): 119983.

[160] A. I. Glembocki and G. R. Somers, “Prognostic and Predictive Biomarkers in Paediatric Solid Tumours,” Pathology 56, no. 2 (2024): 283–296.

[161] S. M. Pfister, M. Reyes-Múgica, J. K. C. Chan, et al., “A Summary of the Inaugural WHO Classification of Pediatric Tumors: Transitioning From the Optical Into the Molecular Era,” Cancer Discovery 12, no. 2 (2022): 331–355.

[162] K. Alvarez, S. F. Kash, M. A. Lyons-Weiler, et al., “Reproducibility and Performance of Virtual Karyotyping With SNP Microarrays for the Detection of Chromosomal Imbalances in Formalin-Fixed Paraffin-Embedded Tissues,” Diagnostic Molecular Pathology, Part B 19, no. 3 (2010): 127–134.

[163] Children's National Hospital Leukemia and Lymphoma Program: Clinical Trials, Accessed on January 16, 2025, https://www.childrensnational.org/get-care/departments/leukemia-lymphoma-program/clinical-trials.

[164] S. Fransson, K. Georgantzi, A. Djos, et al., “Comparative Analysis of Whole-Genome Sequencing of Tumor and cfDNA in a Neuroblastoma Patient: A Case Report,” Frontiers in Oncology 15, no. 1569520 (2025), https://doi.org/10.3389/fonc.2025.1569520.

[165] A. Gerrish, C. Mashayamombe-Wolfgarten, E. Stone, et al., “Genetic Diagnosis of Retinoblastoma Using Aqueous Humour-Findings From an Extended Cohort,” Cancers 16, no. 8 (2024): 1565.

[166] C. McLeod, A. M. Gout, X. Zhou, et al., “St. Jude Cloud: A Pediatric Cancer Genomic Data-Sharing Ecosystem,” Cancer Discovery 11, no. 5 (2021): 1082–1099.

[167] G. H. Reaman, “Successful Integration of Cooperative Groups: The Origin of the Children's Oncology Group,” American Society of Clinical Oncology Educational Book 32 (2012): 149–151, American Society of Clinical Oncology. Meeting.

[168] D. S. Shulman, K. Klega, A. Imamovic-Tuco, et al., “Detection of Circulating Tumour DNA Is Associated With Inferior Outcomes in Ewing Sarcoma and Osteosarcoma: A Report From the Children's Oncology Group,” British Journal of Cancer 119, no. 5 (2018): 615–621.

[169] L. M. Madanat-Harjuoja, L. A. Renfro, K. Klega, et al., “Circulating Tumor DNA as a Biomarker in Patients With Stage III and IV Wilms Tumor: Analysis From a Children's Oncology Group Trial, AREN0533,” Journal of Clinical Oncology 40, no. 26 (2022): 3047–3056.

[170] B. C. Worst, C. M. Tilburg, G. P. Balasubramanian, et al., “Next-Generation Personalised Medicine for High-Risk Paediatric Cancer Patients—The INFORM Pilot Study,” European Journal of Cancer (Oxford, England: 1990) 65 (2016): 91–101.

[171] D. Wong, P. Luo, L. E. Oldfield, et al., “Early Cancer Detection in Li–Fraumeni Syndrome With Cell-Free DNA,” Cancer Discovery 14, no. 1 (2024): 104–119.

[172] J. Tie, J. D. Cohen, K. Lahouel, et al., “Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer,” New England Journal of Medicine 386, no. 24 (2022): 2261–2272.

[173] E. S. Kim, R. B. Scharpf, M. Garcia-Closas, K. Visvanathan, V. E. Velculescu, and N. Chatterjee, “Potential Utility of Risk Stratification for Multicancer Screening With Liquid Biopsy Tests,” NPJ Precision Oncology 7, no. 1 (2023), https://doi.org/10.1038/s41698-023-00377-w.

[174] R. Lee and H. A. Robbins, “PATHFINDER: Another Step on the Uncharted Path to Multicancer Screening,” Lancet 402, no. 10409 (2023): 1213–1215.

[175] S. J. Miller, J. R. Sly, C. Rolfo, et al., “Multi-Cancer Early Detection (MCED) Tests: Prioritizing Equity From Bench to Bedside,” Health Affairs Scholar 2, no. 5 (2024), https://doi.org/10.1093/haschl/qxae039.

[176] M. Fagery, H. A. Khorshidi, S. Q. Wong, Ö. Karanfil, J. Emery, and M. J. IJzerman, “Integrating Multi-Cancer Early Detection (MCED) Tests With Standard Cancer Screening: System Dynamics Model Development and Feasibility Testing,” PharmacoEconomics Open 9, no. 1 (2025): 147–160.

[177] C. A. Doubeni, Y. K. Lau, J. S. Lin, G. A. Pennello, and R. W. Carlson, “Development and Evaluation of Safety and Effectiveness of Novel Cancer Screening Tests for Routine Clinical Use With Applications to Multicancer Detection Technologies,” Cancer 128, no. S4 (2022): 883–891.

[178] A. M. Lennon, A. H. Buchanan, I. Kinde, et al., “Feasibility of Blood Testing Combined With PET-CT to Screen for Cancer and Guide Intervention,” Science (New York, NY) 369, no. 6499 (2020), https://doi.org/10.1126/science.abb9601.

[179] F. Bie, Z. Wang, Y. Li, et al., “Multimodal Analysis of Cell-Free DNA Whole-Methylome Sequencing for Cancer Detection and Localization,” Nature Communications 14, no. 1 (2023), https://doi.org/10.1038/s41467-023-41774-w.

[180] M. M. U. D. Malik, M. M. Alqahtani, I. Hadadi, I. Kanbayti, Z. Alawaji, and B. A. Aloufi, “Molecular Imaging Biomarkers for Early Cancer Detection: A Systematic Review of Emerging Technologies and Clinical Applications,” Diagnostics (Basel, Switzerland) 14, no. 21 (2024): 2459.

[181] A. R. Sharkey, A. Pervez, and G. J. R. Cook, “Novel Molecular Imaging Approaches in Oncology: Towards a More Accurate Estimation of Tumour Response,” Current Opinion in Oncology 37, no. 5 (2025): 522–528.

[182] L. Ma, H. Guo, Y. Zhao, et al., “Liquid Biopsy in Cancer: Current Status, Challenges and Future Prospects,” Signal Transduction and Targeted Therapy 9, no. 1 (2024), https://doi.org/10.1038/s41392-024-02021-w.

[183] “Turning the Tide of Early Cancer Detection,” Nature Medicine 30, no. 5 (2024): 1217–1217.

[184] F. Godinez, C. Mingels, R. Bayerlein, B. Mehadji, and L. Nardo, “Total Body PET/CT: Future Aspects,” Seminars in Nuclear Medicine 55, no. 1 (2025): 107–115.

[185] L. Xu, J.-Y. Zhou, L.-L. Wang, R.-N. Yang, T.-X. Li, and X.-L. Zhu, “A Multidimensional Model Incorporating Radiomics Score and Liquid Biopsy for the Prediction of Malignant and Benign Pulmonary Nodules,” Translational Cancer Research 11, no. 11 (2022): 4009–4018.

[186] E. Neri, M. Del Re, F. Paiar, et al., “Radiomics and Liquid Biopsy in Oncology: The Holons of Systems Medicine,” Insights Into Imaging 9, no. 6 (2018): 915–924.

[187] L. Gao, L. Zhang, J. Liu, et al., “Discovery and Validation of Cell-Free DNA Methylation Markers for Specific Diagnosis, Differentiation From Benign Tumors, and Prognosis of Breast Cancer,” Breast Cancer Research 27, no. 1 (2025), https://doi.org/10.1186/s13058-025-02066-x.

[188] S. D. Ramsey, J. W. Friedberg, J. V. Cox, and J. M. Peppercorn, “Economic Analysis of Screening, Diagnostic, and Treatment Technologies for Cancer: Reflections and a Roadmap for Prospective Authors,” Journal of Clinical Oncology 41, no. 1 (2023): 3–6.

[189] S. Zhang, X. Wang, X. Gao, et al., “Radiopharmaceuticals and Their Applications in Medicine,” Signal Transduction and Targeted Therapy 10, no. 1 (2025), https://doi.org/10.1038/s41392-024-02041-6.

RIGHTS & PERMISSIONS

2026 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.